The Claim
In adults with type 2 diabetes, treatment with tirzepatide at doses of 5 mg and higher significantly increases circulating levels of adiponectin, IGFBP-1, and IGFBP-2 compared to treatment with dulaglutide.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with type 2 diabetes, a medication called tirzepatide at doses of 5 mg or higher raises levels of certain blood proteins—adiponectin, IGFBP-1, and IGFBP-2—more than another medication called dulaglutide. These proteins are linked to better insulin sensitivity.
See the scientific wording
In adults with type 2 diabetes, tirzepatide at doses of 5 mg and higher significantly increases circulating adiponectin and insulin-like growth factor binding proteins IGFBP-1 and IGFBP-2, biomarkers associated with improved insulin sensitivity, to a greater extent than dulaglutide.
Tirzepatide activates two specific receptors on fat cells and liver cells, which causes the fat cells to release more of a protein called adiponectin and the liver to release more of two other proteins called IGFBP-1 and IGFBP-2. These proteins help the body use insulin more effectively, allowing blood sugar to be taken up by muscles and fat without needing as much insulin.
What the research says
1 studyIn people with type 2 diabetes, tirzepatide boosts levels of certain blood proteins that help the body respond better to insulin, and it does this better than another similar drug called dulaglutide.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.